急性髓系白血病患者原发性mdr_1基因产物P_(-170)与CD_(34)表达及预后的关系  

Relationship between clinical prognosis and expression of P -170 and CD 34 in patients with primary acute myeloblastic leukemia

作　　者：安峻峰[1,2] 张淑兰[1,2] 安红梅 周有普[1,2] 刘国勋 朱绮文[1,2] 陈永振 杨勤[1,2] 

机构地区：[1]广东医学院附属医院内科 [2]宁夏海原县中医院

出　　处：《广东医学院学报》1999年第1期11-14,共4页Journal of Guangdong Medical College

基　　金：广东医学院基金

摘　　要：目的：观察急性髓系白血病（ＡＭＬ）患者原发性ｍｄｒ１基因产物Ｐ－１７０与ＣＤ３４抗原表达与预后的关系。方法：常规分离３１例急性髓系白血病细胞，然后分别进行细胞免疫化学检查，观察了细胞膜分化抗原变化和ｍｄｒ１基因产物Ｐ－１７０反应。结果：Ｐ－１７０总体表达率为４１．９４％，以Ｍ５最高，Ｍ３最低；Ｐ－１７０阳性的白血病患者临床耐药发生率较Ｐ－１７０阴性者高（Ｐ＜０．００１），ＣＤ３４表达者耐药发生率也很高（较ＣＤ３４阴性者，Ｐ＜０．０１）。结论：Ｐ－１７０和ＣＤ３４表达是急性髓系白血病患者对化疗抵抗的标志。Objective:To examine relationship between clinical prognosis and expression of P -170 and CD 34 in primary acute myeloblastic leukemia(AML)patients.Methods:Specimens from 31 AML patients were examined for the expression of AML cells membrane antigens and P -170 by using immunocytochemisty assay.Results:(1)The P -170 positive rate was 41.94% in AML,with the highest incidence in M 5 and the lowest in M 3;(2)the patients with the P -170 positive had higher resistant rate to chemotherapy as compared with the P -170 negative group ( P <0.001).In addition,the CD 34 positive patients also had higher resistant rate to chemotherapy(as compared with the CD 34 negative group.( P <0.01) Conclusion:It suggested that the expression of P -170 and CD 34 in AML is a indicator for resistant response to chemotherapy.

关 键 词：急性 髓系白血病 P-170 MDR1基因 CD34 

分 类 号：R733.710.2[医药卫生—肿瘤]